Collectively, our findings bring further argument for considering the SETD2 gene status of ccRCC tumors, when therapeutic interventions, such as targeting the autophagic process, are considered to combat these kidney cancers. This evidence concerns the gene SETD2 and nonpapillary renal cell carcinoma.